Tao Synergies Inc (TAOX)

$5.95 -0.26 (-4.19%)
Market Cap 21.66M
Revenue (ttm) 0.00
Net Income (ttm) -12.77M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 253,300
Avg Vol 290,172
Day's Range N/A - N/A
Shares Out 3.49M
Stochastic %K 51%
Beta 1.87
Analysts Strong Buy
Price Target N/A

Company Profile

TAO Synergies Inc. owns and operates an AI token. The company executes a cryptocurrency treasury strategy centered on the acquisition and staking of the TAO token, the native utility token of the Bittensor network. TAO Synergies Inc. was formerly known as Synaptogenix, Inc. and changed its name to TAO Synergies Inc. in June 2025. The company was incorporated in 2012 and is headquartered in New York, New York.

Industry: Software - Infrastructure
Sector: Technology
Phone: 973 242 0005
Address:
1185 Avenue of the Americas, 3rd Floor, New York, United States
flagpolesitta
flagpolesitta Sep. 16 at 11:35 AM
$TAOX https://coinpedia.org/price-prediction/bittensor-tao-price-prediction/
0 · Reply
EndGame1
EndGame1 Sep. 16 at 2:29 AM
$TAOX I've been trying to understand my investment in TAOX a little better by reading the Q2 filing. As I see it, the company had accumulated 42,111 Bittensor (TAO) tokens on August 5th, 2025. By Aug 12 they owned 42,463 coins. I assume they own more today. https://ir.taosynergies.com/tao-synergies-accelerates-decentralized-ai-treasury-strategy-with-42111-bittensor-tao-tokens-acquired-and-earned-through-staking-to-date/
0 · Reply
EndGame1
EndGame1 Sep. 15 at 2:54 PM
$TAOX Price hit $6.52 today. I'm buying this dip making it my fourth largest portfolio holding. I think it can see $7 quickly.
0 · Reply
jaltucher
jaltucher Sep. 12 at 5:10 PM
Introducing $TAOX which is the only public company focused on buying the leading crypto AI token. $TAO.X . If anyone has any questions, feel free to ask me as I am helping run their strategy. Haven't been on Stocktwits in awhile so excited to be back with something I can talk about.
9 · Reply
jaltucher
jaltucher Sep. 12 at 4:01 PM
With $TAOX my goal is to buy as much $TAO crypto as possible. I've been writing about TAO for almost three years. Its the leading crypto/AI token. Decentralized AI is a bigger and bigger % of all spending on AI and TAO is the leader. And $TAOX is the biggest public co focusing on this ecosystem.
0 · Reply
jaltucher
jaltucher Sep. 12 at 4:00 PM
Haven't been here in awhile but I'm happy to answer questions about two public DATs that I'm managing: $TAOX and $SBLX. More details in followup tweets.
2 · Reply
SnoopyPotter
SnoopyPotter Sep. 11 at 8:41 PM
$TAOX shows 107% dark pool activity & bullish sentiment as of 9/11/25! With TAO crypto focus & potential Fed rate cut, could be a breakout play. NFA. #TAOX #TAO #Bitcoin #Crypto
0 · Reply
breakoutstock
breakoutstock Sep. 11 at 1:45 PM
$TAOX if you don’t understand this ask Grok to explain it to you as if you were in high school. Now I understand. Massive upside. This is the backbone of the future AI.
0 · Reply
ug24u
ug24u Sep. 11 at 1:44 AM
$TAOX Yes I definitely like what I see, this will have a great run for sure! Loading up on this one.
0 · Reply
SnoopyPotter
SnoopyPotter Sep. 10 at 7:24 PM
$TAOX Google-Hosted Planet Scale Consumer AI Conference in Toronto At the Google-hosted Planet Scale Consumer AI event in Toronto, James Altucher of TAO Synergies (Nasdaq: TAOX) joined Google and prominent subnet founders from Dippy AI (#11), Manifold Labs (#5), and Viggle on stage. His key points: AI Market Growth: Global AI spending is projected to surge from $300 billion to $30 trillion by 2030. Decentralized AI's Rise: Decentralized AI (DeAI) is capturing an increasing share of this market each year. TAO's Leadership: $TAO is positioning itself as the backbone of the DeAI ecosystem. While debates over "closed vs. open" AI models persist, $TAO is steadily integrating itself as a foundational layer of the AI economy. This isn’t speculation—it’s the infrastructure buildout for the future of AI.
1 · Reply
Latest News on TAOX
TAO Synergies Digital Assets Advisor James Altucher Speaks at Google's Planet Scale Consumer AI Event

Sep 8, 2025, 9:15 AM EDT - 7 days ago

TAO Synergies Digital Assets Advisor James Altucher Speaks at Google's Planet Scale Consumer AI Event

TAO Synergies Welcomes Top Bittensor (TAO) Leader as Advisor for AI-Focused Crypto Treasury Strategy

Aug 26, 2025, 9:15 AM EDT - 20 days ago

TAO Synergies Welcomes Top Bittensor (TAO) Leader as Advisor for AI-Focused Crypto Treasury Strategy

TAO Synergies (Formerly Synaptogenix) Begins Trading Under New Nasdaq Stock Symbol "TAOX" Effective at Market Open Today

Jul 1, 2025, 9:15 AM EDT - 2 months ago

TAO Synergies (Formerly Synaptogenix) Begins Trading Under New Nasdaq Stock Symbol "TAOX" Effective at Market Open Today

Synaptogenix Announces Name Change to TAO Synergies and New Ticker Symbol "TAOX" for Alignment with AI-Focused Crypto Treasury Strategy

Jun 26, 2025, 9:15 AM EDT - 2 months ago

Synaptogenix Announces Name Change to TAO Synergies and New Ticker Symbol "TAOX" for Alignment with AI-Focused Crypto Treasury Strategy

Synaptogenix Announces Initial TAO Acquisition under Crypto Treasury Strategy, Appoints BitGo as Custodian, and Commences Yield Generation Through Staking

Jun 24, 2025, 9:15 AM EDT - 2 months ago

Synaptogenix Announces Initial TAO Acquisition under Crypto Treasury Strategy, Appoints BitGo as Custodian, and Commences Yield Generation Through Staking

Synaptogenix Appoints Crypto Expert to Lead Digital Asset Treasury Strategy Focused Exclusively on Top-Valued AI Token

Jun 9, 2025, 9:00 AM EDT - 3 months ago

Synaptogenix Appoints Crypto Expert to Lead Digital Asset Treasury Strategy Focused Exclusively on Top-Valued AI Token

Synaptogenix Board of Directors Forms Special Committee to Explore Value Creation Opportunities Utilizing Balance Sheet Strength

Dec 20, 2024, 9:15 AM EST - 9 months ago

Synaptogenix Board of Directors Forms Special Committee to Explore Value Creation Opportunities Utilizing Balance Sheet Strength

Synaptogenix Announces $5.0 Million Financing

Sep 11, 2024, 9:00 AM EDT - 1 year ago

Synaptogenix Announces $5.0 Million Financing

Synaptogenix Announces New Collaboration with LSU Health New Orleans for Study of Proprietary Analogs in Spinal Cord Injury

Jul 18, 2024, 9:00 AM EDT - 1 year ago

Synaptogenix Announces New Collaboration with LSU Health New Orleans for Study of Proprietary Analogs in Spinal Cord Injury

Synaptogenix Announces FDA Authorization of IND Application for Clinical Trial for Bryostatin-1 in Multiple Sclerosis

Jun 26, 2024, 9:00 AM EDT - 1 year ago

Synaptogenix Announces FDA Authorization of IND Application for Clinical Trial for Bryostatin-1 in Multiple Sclerosis

Synaptogenix Applauds DEA Proposal to Reclassify Cannabis and Shares Expected Benefits to Cannasoul for Cannabinoid-Based Drug Discovery

May 7, 2024, 9:00 AM EDT - 1 year ago

Synaptogenix Applauds DEA Proposal to Reclassify Cannabis and Shares Expected Benefits to Cannasoul for Cannabinoid-Based Drug Discovery

Synaptogenix Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing

Apr 24, 2024, 9:15 AM EDT - 1 year ago

Synaptogenix Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing

Synaptogenix Announces Reverse Stock Split to Maintain Nasdaq Listing

Apr 3, 2024, 8:00 AM EDT - 1 year ago

Synaptogenix Announces Reverse Stock Split to Maintain Nasdaq Listing

Synaptogenix President Daniel L. Alkon, M.D.

Dec 19, 2023, 9:00 AM EST - 1 year ago

Synaptogenix President Daniel L. Alkon, M.D.

Synaptogenix Joins Leading Neuroscientists and Academics as Speaker at USC-Sponsored Forum on Age-Related Diseases including Alzheimer's

Dec 6, 2023, 9:00 AM EST - 1 year ago

Synaptogenix Joins Leading Neuroscientists and Academics as Speaker at USC-Sponsored Forum on Age-Related Diseases including Alzheimer's

Synaptogenix Acquires Significant Stake in Cannasoul Analtyics Ltd. Co-founded by The Technion - Israel Institute of Technology

Nov 2, 2023, 9:00 AM EDT - 2 years ago

Synaptogenix Acquires Significant Stake in Cannasoul Analtyics Ltd. Co-founded by The Technion - Israel Institute of Technology

Synaptogenix Announces Peer-Reviewed Publication of NIH-Sponsored Phase 2 Clinical Trial Results Demonstrating Safe, Significant, and Persistent Benefits of Bryostatin-1 in Advanced Alzheimer's Disease

Sep 26, 2023, 9:00 AM EDT - 2 years ago

Synaptogenix Announces Peer-Reviewed Publication of NIH-Sponsored Phase 2 Clinical Trial Results Demonstrating Safe, Significant, and Persistent Benefits of Bryostatin-1 in Advanced Alzheimer's Disease

Bryostatin-1 from Synaptogenix Shows Statistically Significant Results as an ALS Treatment in Pre-Clinical Independent Study

Sep 7, 2023, 9:00 AM EDT - 2 years ago

Bryostatin-1 from Synaptogenix Shows Statistically Significant Results as an ALS Treatment in Pre-Clinical Independent Study

Synaptogenix and Cleveland Clinic to Submit Investigational New Drug (IND) Application to FDA for Clinical Trial of Bryostatin-1 in Multiple Sclerosis

Jul 19, 2023, 9:00 AM EDT - 2 years ago

Synaptogenix and Cleveland Clinic to Submit Investigational New Drug (IND) Application to FDA for Clinical Trial of Bryostatin-1 in Multiple Sclerosis

Synaptogenix Abstract Highlighting Bryostatin-1 Benefits in Severe Alzheimer's Disease Accepted for Presentation at 11th International Brain Research Organization World Congress of Neuroscience

Jul 13, 2023, 9:00 AM EDT - 2 years ago

Synaptogenix Abstract Highlighting Bryostatin-1 Benefits in Severe Alzheimer's Disease Accepted for Presentation at 11th International Brain Research Organization World Congress of Neuroscience

Synaptogenix Provides Corporate Update and Outlines Potential Business Opportunities

Mar 7, 2023, 9:00 AM EST - 2 years ago

Synaptogenix Provides Corporate Update and Outlines Potential Business Opportunities

5 Health Care Stocks That Are Diving - And May Rally

Jan 19, 2023, 8:58 AM EST - 2 years ago

5 Health Care Stocks That Are Diving - And May Rally

FATE IPSC TECH

Synaptogenix Announces Topline Results from NIH-Sponsored Phase 2 Clinical Trial of Bryostatin-1 for Advanced Alzheimer's Disease

Dec 16, 2022, 9:00 AM EST - 2 years ago

Synaptogenix Announces Topline Results from NIH-Sponsored Phase 2 Clinical Trial of Bryostatin-1 for Advanced Alzheimer's Disease

Synaptogenix: Bryostatin For Alzheimer's, As Binary As Can Be

Dec 9, 2022, 11:50 AM EST - 3 years ago

Synaptogenix: Bryostatin For Alzheimer's, As Binary As Can Be

Synaptogenix Announces $15 Million Private Placement with Existing Investors

Nov 18, 2022, 9:00 AM EST - 3 years ago

Synaptogenix Announces $15 Million Private Placement with Existing Investors

Synaptogenix to Present at ThinkEquity Investor Conference on October 26, 2022

Oct 19, 2022, 9:00 AM EDT - 3 years ago

Synaptogenix to Present at ThinkEquity Investor Conference on October 26, 2022

Synaptogenix Welcomes Lecanemab Phase 3 Trial Results

Sep 28, 2022, 11:50 AM EDT - 3 years ago

Synaptogenix Welcomes Lecanemab Phase 3 Trial Results

Synaptogenix Announces Live Appearance of its President and CSO on Streaming Financial News Network

Aug 12, 2022, 9:00 AM EDT - 3 years ago

Synaptogenix Announces Live Appearance of its President and CSO on Streaming Financial News Network

Synaptogenix Announces Changes to Scientific Advisory Board in Preparation for Phase 2 Data

Jul 26, 2022, 9:15 AM EDT - 3 years ago

Synaptogenix Announces Changes to Scientific Advisory Board in Preparation for Phase 2 Data

Synaptogenix Announces Corporate Update Conference Call

Jul 21, 2022, 9:15 AM EDT - 3 years ago

Synaptogenix Announces Corporate Update Conference Call

Synaptogenix Advances Dosing of First Patient in Dose Optimization Clinical Trial in Preparation for NIH-Sponsored, Phase 2 Alzheimer's Disease Trial Data

Jul 20, 2022, 9:15 AM EDT - 3 years ago

Synaptogenix Advances Dosing of First Patient in Dose Optimization Clinical Trial in Preparation for NIH-Sponsored, Phase 2 Alzheimer's Disease Trial Data

Synaptogenix to Present at the Cell Symposium

May 17, 2022, 9:15 AM EDT - 3 years ago

Synaptogenix to Present at the Cell Symposium

Synaptogenix Completes Patient Enrollment in NIH Sponsored Phase 2b Alzheimer's Disease Trial

Apr 19, 2022, 9:15 AM EDT - 3 years ago

Synaptogenix Completes Patient Enrollment in NIH Sponsored Phase 2b Alzheimer's Disease Trial

New Peer Reviewed Article Demonstrates Extended Therapeutic Potential of Synaptogenix's Bryostatin for Alzheimer's Disease

Apr 5, 2022, 9:15 AM EDT - 3 years ago

New Peer Reviewed Article Demonstrates Extended Therapeutic Potential of Synaptogenix's Bryostatin for Alzheimer's Disease

Synaptogenix to Present at Hanson Wade 10th Annual Neurodegenerative Drug Development Summit

Mar 29, 2022, 9:15 AM EDT - 3 years ago

Synaptogenix to Present at Hanson Wade 10th Annual Neurodegenerative Drug Development Summit

Synaptogenix to Present at Sachs 5th Annual Neuroscience Innovation Forum

Mar 22, 2022, 9:15 AM EDT - 3 years ago

Synaptogenix to Present at Sachs 5th Annual Neuroscience Innovation Forum

Synaptogenix to Present Research Highlighting Potential Broad Applicability for Lead Compound Bryostatin at the International Conference on Alzheimer's and Parkinson's Diseases (AD/PD 2022)

Mar 15, 2022, 9:15 AM EDT - 3 years ago

Synaptogenix to Present Research Highlighting Potential Broad Applicability for Lead Compound Bryostatin at the International Conference on Alzheimer's and Parkinson's Diseases (AD/PD 2022)

Synaptogenix Moves Forward with Clinical Development Plans for Bryostatin-1 as a Treatment for Multiple Sclerosis

Feb 23, 2022, 9:15 AM EST - 3 years ago

Synaptogenix Moves Forward with Clinical Development Plans for Bryostatin-1 as a Treatment for Multiple Sclerosis

Synaptogenix Announces Publication of Peer-Reviewed Scientific Article Evidencing Byrostatin-1's Improved Cognition Over Baseline in Advanced Alzheimer's Disease Patients

Feb 1, 2022, 9:15 AM EST - 3 years ago

Synaptogenix Announces Publication of Peer-Reviewed Scientific Article Evidencing Byrostatin-1's Improved Cognition Over Baseline in Advanced Alzheimer's Disease Patients

Synaptogenix: High-Risk High-Reward For Potential Alzheimer's Disease Treatment

Nov 16, 2021, 11:07 PM EST - 4 years ago

Synaptogenix: High-Risk High-Reward For Potential Alzheimer's Disease Treatment

5 Short Squeeze Candidates To Watch: Huadi Tops List, Altimeter Group And Bit Digital Rejoin Leaderboard

Nov 15, 2021, 9:28 AM EST - 4 years ago

5 Short Squeeze Candidates To Watch: Huadi Tops List, Altimeter Group And Bit Digital Rejoin Leaderboard

BTBT HUDI

Rebuilding Connections, Fostering Growth: Synaptogenix Could Be A Beacon of Hope for Patients With Neurological Diseases

Oct 5, 2021, 9:14 AM EDT - 4 years ago

Rebuilding Connections, Fostering Growth: Synaptogenix Could Be A Beacon of Hope for Patients With Neurological Diseases

Synaptogenix Announces Participation at the H.C. Wainwright 23rd Annual Global Investment Conference

Sep 10, 2021, 9:00 AM EDT - 4 years ago

Synaptogenix Announces Participation at the H.C. Wainwright 23rd Annual Global Investment Conference

Synaptogenix Signs Memorandum Of Understanding with Nemours A.I. DuPont Hospital to Initiate Trial Using Bryostatin, Under Orphan Drug Status, to Treat Fragile X Syndrome

Aug 5, 2021, 10:00 AM EDT - 4 years ago

Synaptogenix Signs Memorandum Of Understanding with Nemours A.I. DuPont Hospital to Initiate Trial Using Bryostatin, Under Orphan Drug Status, to Treat Fragile X Syndrome

Synaptogenix Stock Drops After Unveiling Analyses Of Alzheimer's Candidate

Jul 26, 2021, 1:47 PM EDT - 4 years ago

Synaptogenix Stock Drops After Unveiling Analyses Of Alzheimer's Candidate

Synaptogenix Discloses Positive Results of Further Bryostatin Trial Analyses in Presentation at Alzheimer's Association International Conference 2021

Jul 26, 2021, 9:15 AM EDT - 4 years ago

Synaptogenix Discloses Positive Results of Further Bryostatin Trial Analyses in Presentation at Alzheimer's Association International Conference 2021

Synaptogenix Announces Conference Call to Discuss AAIC Abstract Findings

Jul 21, 2021, 9:00 AM EDT - 4 years ago

Synaptogenix Announces Conference Call to Discuss AAIC Abstract Findings

Synaptogenix to Present Data at Alzheimer's Association International Conference 2021 Highlighting Bryostatin Restores Cognitive Function Above Baseline

Jul 14, 2021, 9:00 AM EDT - 4 years ago

Synaptogenix to Present Data at Alzheimer's Association International Conference 2021 Highlighting Bryostatin Restores Cognitive Function Above Baseline

Synaptogenix Announces Regenerative Patent Award to Treat Alzheimer's Disease

Jul 7, 2021, 9:00 AM EDT - 4 years ago

Synaptogenix Announces Regenerative Patent Award to Treat Alzheimer's Disease

Synaptogenix: The Next Big Thing In Alzheimer's

Jun 16, 2021, 4:06 PM EDT - 4 years ago

Synaptogenix: The Next Big Thing In Alzheimer's

flagpolesitta
flagpolesitta Sep. 16 at 11:35 AM
$TAOX https://coinpedia.org/price-prediction/bittensor-tao-price-prediction/
0 · Reply
EndGame1
EndGame1 Sep. 16 at 2:29 AM
$TAOX I've been trying to understand my investment in TAOX a little better by reading the Q2 filing. As I see it, the company had accumulated 42,111 Bittensor (TAO) tokens on August 5th, 2025. By Aug 12 they owned 42,463 coins. I assume they own more today. https://ir.taosynergies.com/tao-synergies-accelerates-decentralized-ai-treasury-strategy-with-42111-bittensor-tao-tokens-acquired-and-earned-through-staking-to-date/
0 · Reply
EndGame1
EndGame1 Sep. 15 at 2:54 PM
$TAOX Price hit $6.52 today. I'm buying this dip making it my fourth largest portfolio holding. I think it can see $7 quickly.
0 · Reply
jaltucher
jaltucher Sep. 12 at 5:10 PM
Introducing $TAOX which is the only public company focused on buying the leading crypto AI token. $TAO.X . If anyone has any questions, feel free to ask me as I am helping run their strategy. Haven't been on Stocktwits in awhile so excited to be back with something I can talk about.
9 · Reply
jaltucher
jaltucher Sep. 12 at 4:01 PM
With $TAOX my goal is to buy as much $TAO crypto as possible. I've been writing about TAO for almost three years. Its the leading crypto/AI token. Decentralized AI is a bigger and bigger % of all spending on AI and TAO is the leader. And $TAOX is the biggest public co focusing on this ecosystem.
0 · Reply
jaltucher
jaltucher Sep. 12 at 4:00 PM
Haven't been here in awhile but I'm happy to answer questions about two public DATs that I'm managing: $TAOX and $SBLX. More details in followup tweets.
2 · Reply
SnoopyPotter
SnoopyPotter Sep. 11 at 8:41 PM
$TAOX shows 107% dark pool activity & bullish sentiment as of 9/11/25! With TAO crypto focus & potential Fed rate cut, could be a breakout play. NFA. #TAOX #TAO #Bitcoin #Crypto
0 · Reply
breakoutstock
breakoutstock Sep. 11 at 1:45 PM
$TAOX if you don’t understand this ask Grok to explain it to you as if you were in high school. Now I understand. Massive upside. This is the backbone of the future AI.
0 · Reply
ug24u
ug24u Sep. 11 at 1:44 AM
$TAOX Yes I definitely like what I see, this will have a great run for sure! Loading up on this one.
0 · Reply
SnoopyPotter
SnoopyPotter Sep. 10 at 7:24 PM
$TAOX Google-Hosted Planet Scale Consumer AI Conference in Toronto At the Google-hosted Planet Scale Consumer AI event in Toronto, James Altucher of TAO Synergies (Nasdaq: TAOX) joined Google and prominent subnet founders from Dippy AI (#11), Manifold Labs (#5), and Viggle on stage. His key points: AI Market Growth: Global AI spending is projected to surge from $300 billion to $30 trillion by 2030. Decentralized AI's Rise: Decentralized AI (DeAI) is capturing an increasing share of this market each year. TAO's Leadership: $TAO is positioning itself as the backbone of the DeAI ecosystem. While debates over "closed vs. open" AI models persist, $TAO is steadily integrating itself as a foundational layer of the AI economy. This isn’t speculation—it’s the infrastructure buildout for the future of AI.
1 · Reply
macamo68
macamo68 Sep. 10 at 7:54 AM
$TAOX https://youtu.be/D_8VOzxsGRQ?si=Bk7kAd_IxP3AtB_v
0 · Reply
SnoopyPotter
SnoopyPotter Sep. 10 at 3:19 AM
$TAOX The high 128.57% dark pool activity suggests: • Institutional accumulation or positioning: Whales (e.g., hedge funds) are quietly building or adjusting large positions in TAOX shares, possibly betting on Bittensor’s AI growth (TAO token is up ~60% YTD as of Sept 2025). The “down” trend might reflect short-term public market pressure, but dark pools often precede bullish moves. https://x.com/bitcoinonwards/status/1965103684540662086?s=46
0 · Reply
breakoutstock
breakoutstock Sep. 10 at 3:11 AM
$TAOX I’m accumulating this. Massive massive potential.
2 · Reply
SnoopyPotter
SnoopyPotter Sep. 10 at 2:30 AM
$TAOX https://x.com/barrysilbert/status/1965544232502132879?s=46 Bittensor in Forbes
0 · Reply
TaoistTrader
TaoistTrader Sep. 9 at 11:58 PM
https://youtube.com/watch?v=HJEE6IQ3oA4&si=z5Eu7xPELZsFDsgm $TAOX $TAO.X
0 · Reply
SnoopyPotter
SnoopyPotter Sep. 9 at 1:54 PM
$TAOX Bittensor Revenue Search 25: James Altucher siamkidd @SiamKiddhttps://x.com/i/broadcasts/1nAKEENjvmYKL#:~:text=Bittensor%20Revenue%20Search%2025%3A%20James%20Altucher
1 · Reply
TaoistTrader
TaoistTrader Sep. 8 at 9:52 PM
$TAOX our man James is spreading the good word. I’ve listened to his podcast for years now, interesting guy and sharp.
0 · Reply
prismmarketview
prismmarketview Sep. 5 at 5:41 PM
$TAOX
0 · Reply
souldout
souldout Sep. 3 at 5:43 PM
$TAOX TAO SYNERGIES Tao Treasury ran by James Altucher $TAO.X is bouncing guys. Buy low $DFDV $HODL.CSE
0 · Reply
souldout
souldout Sep. 3 at 4:06 PM
$TAOX $TAO.X is bouncing strong from the lows. Load up Tao Synergies it follows right after Bottom is in.. $OBLG $DFDV
0 · Reply
WinWithFlynn
WinWithFlynn Sep. 3 at 3:41 AM
$TAOX
0 · Reply
_www_larval_com_
_www_larval_com_ Sep. 2 at 1:52 PM
$TAOX just popped 12% higher to 8% (~61Kv) a few minutes ago, follow for more volatility.
0 · Reply